CURB-2 Trial Open for Recruitment for Moderate/Heavy Cocaine Use Disorder Patients

Researchers at the University of Illinois Chicago are studying whether treatment with injectable extended-release naltrexone (XR-NTX; Vivitrol®) and injectable extended-release Buprenorphine (XR-BUP; Sublocade®) is safe and effective for helping people to cut down or stop using cocaine. Researchers believe the combination of these medications may reduce cocaine withdrawal symptoms.  

The CURB-2 Study is a phase 2, randomized, placebo-controlled trial. Individuals may be eligible to participate if they: 

      - Are between the ages of 18 - 65 

      - Use cocaine regularly and interested in cutting down or stopping cocaine use

      - Are able to attend in-person appointments on the UIC campus for approximately 16 weeks

There is no cost to participate in this study.  The time and contribution of participants will be of tremendous value to public health research. Eligible individuals will be compensated up to a total of $968 for completed study activities. 

Potential participants can call 312.355.4055 or follow the link below to learn more about the study and apply for potential participation:   

https://redcap.link/curb2

Principal Investigator: Dr. Niranjan Karnik, Department of Psychiatry, UIC IRB Protocol #2022-0905